Loading…
Cellectis S.A. is projected to rise to $4.59 by 2027, a +26% move from its current price of $3.63. CLLS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.52 | $3.63 | $3.74 | +0.01% |
| May 30 | $3.48 | $3.63 | $3.79 | +0.02% |
| May 31 | $3.44 | $3.63 | $3.83 | +0.03% |
| Jun 1 | $3.42 | $3.63 | $3.86 | +0.04% |
| Jun 2 | $3.39 | $3.63 | $3.89 | +0.06% |
| Jun 3 | $3.37 | $3.63 | $3.91 | +0.07% |
| Jun 4 | $3.35 | $3.63 | $3.94 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.35 | $3.63 | $3.94 | +0.08% |
| Week 2 | $3.24 | $3.64 | $4.07 | +0.15% |
| Week 3 | $3.17 | $3.64 | $4.18 | +0.23% |
| Week 4 | $3.10 | $3.64 | $4.28 | +0.31% |
| Week 5 | $3.04 | $3.64 | $4.36 | +0.39% |
| Week 6 | $2.99 | $3.65 | $4.44 | +0.47% |
| Week 7 | $2.95 | $3.65 | $4.52 | +0.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cellectis S.A. is a clinical stage biotechnological company that develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma.
Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis S.A. (CLLS) is currently trading at $3.50, with a market cap of $352.14M.
The stock is ranked 3356 in market capitalization terms among listed equities.
The near-term price outlook sits with bearish technical sentiment, as indicated by current levels around key moving averages. The SMA50 sits at $3.71 and the SMA200 at $3.77, with a visible 30-day range and immediate support/resistance levels.
A major floor 19.3% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 21.8% above — a clean break opens room to run.
A major ceiling 31.4% above — clearing it would confirm fresh momentum.
Key CLLS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLLS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.60 | Buy | $3.64 | Sell |
| MA 10 | $3.74 | Sell | $3.70 | Sell |
| MA 20 | $3.80 | Sell | $3.77 | Sell |
| MA 50 | $3.71 | Sell | $3.79 | Sell |
| MA 100 | $3.83 | Sell | $3.79 | Sell |
| MA 200 | $3.78 | Sell | $3.56 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.58 | Neutral |
| Stoch RSI (14) | 30.70 | Neutral |
| CCI (20) | -80.80 | Neutral |
| Williams %R (14) | -77.19 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -5.71 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 22.81 | Neutral |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | -0.29 | Sell |
| Ultimate (7,14,28) | 32.66 | Neutral |
| Momentum (10) | -0.33 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 3.52 | Buy |
| ADX (14) | 11.22 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is bearish.
RSI(14) is 40, and prices are trading nearby the SMA50 of $3.71 and the SMA200 of $3.77, suggesting softness in the near term. The price currently sits at $3.50, with a nearby support at $3.50 and a resistance at $4.42. The 30-day range spans from $2.86 to $4.28, highlighting notable upside potential but also downside risk in the month ahead.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.08 | $3.63 | $5.11 | 0% | Neutral | |
| $3.60 | $4.59 | $6.22 | +26% | Bullish | |
| $4.04 | $5.32 | $7.50 | +46% | Bullish | |
| $4.64 | $6.26 | $9.10 | +72% | Bullish | |
| $4.33 | $5.98 | $8.92 | +65% | Bullish | |
| $4.28 | $6.03 | $9.21 | +66% | Bullish | |
| $4.72 | $6.78 | $10.56 | +87% | Bullish | |
| $4.66 | $6.82 | $10.82 | +88% | Bullish | |
| $5.55 | $8.26 | $13.34 | +128% | Bullish | |
| $6.38 | $9.67 | $15.86 | +166% | Bullish | |
| $7.10 | $11.62 | $20.37 | +220% | Bullish | |
| $13.88 | $26.01 | $50.17 | +617% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.08 | $3.63 | $4.27 | +0.00% |
| June 2026 | $3.06 | $3.61 | $4.36 | -0.60% |
| July 2026 | $3.09 | $3.67 | $4.49 | +1.62% |
| August 2026 | $3.25 | $3.89 | $4.82 | +6.08% |
| September 2026 | $3.28 | $3.95 | $4.95 | +1.65% |
| October 2026 | $3.19 | $3.86 | $4.87 | -2.27% |
| November 2026 | $3.21 | $3.91 | $4.97 | +1.24% |
| December 2026 | $3.26 | $3.99 | $5.11 | +2.02% |
Click any year to see its month-by-month CLLS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CLLS price prediction for 2026 points to an average of $3.63 (low $3.08, high $5.11) — a potential gain of 0% on today's $3.63. A consolidation phase looks the most probable path here.
In 2027, CLLS is projected to trade between $3.60 and $6.22, averaging $4.59 — a potential gain of +26% from today's $3.63. That is up +26% on the projected 2026 average. Momentum favours further upside here.
Cellectis S.A.'s 2028 outlook centres on $5.32, within a $4.04 to $7.50 range. That is up +16% on the projected 2027 average. That marks a +46% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CLLS could reach as high as $9.10, with a base case around $6.26 and support toward $4.64 — roughly +72% from $3.63. Momentum favours further upside here.
Expect CLLS to range from $4.33 to $8.92 through 2030. The $5.98 average target implies a +65% move from current prices. That is -4% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The CLLS price prediction for 2031 points to an average of $6.03 (low $4.28, high $9.21) — a potential gain of +66% on today's $3.63. Momentum favours further upside here.
In 2032, CLLS is projected to trade between $4.72 and $10.56, averaging $6.78 — a potential gain of +87% from today's $3.63. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Cellectis S.A.'s 2033 outlook centres on $6.82, within a $4.66 to $10.82 range. That is up +1% on the projected 2032 average. That marks a +88% change versus current levels. Momentum favours further upside here.
By 2034, CLLS could reach as high as $13.34, with a base case around $8.26 and support toward $5.55 — roughly +128% from $3.63. Buyers look set to stay in control over this stretch.
Expect CLLS to range from $6.38 to $15.86 through 2035. The $9.67 average target implies a +166% move from current prices. That is up +17% on the projected 2034 average. Momentum favours further upside here.
The CLLS price prediction for 2040 points to an average of $11.62 (low $7.10, high $20.37) — a potential gain of +220% on today's $3.63. Buyers look set to stay in control over this stretch.
In 2050, CLLS is projected to trade between $13.88 and $50.17, averaging $26.01 — a potential gain of +617% from today's $3.63. That is up +124% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CLLS today (≈ 275.482094 CLLS) could be worth
$7,165.45
+$6,165.45 (+617%) by 2050 · US Dollar
Based on the average projected CLLS price of $26.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLLSwould be worth at today's price.
$1,000 invested in CLLS on May 27, 2025 (≈ 684.931489 CLLS) would be worth
$2,486.3
+$1,486.3 (+148.6%) today · 2.49× · US Dollar
Based on a CLLS entry price of $1.46 vs. today's $3.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.66 | $991.8 | -0.8% |
| 1 month ago | $4.01 | $905.24 | -9.5% |
| 3 months ago | $4.02 | $902.99 | -9.7% |
| 6 months ago | $5.07 | $715.98 | -28.4% |
| 1 year ago | $1.46 | $2,486.3 | +148.6% |
| All time (5.0y) ago | $16.35 | $222.02 | -77.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLLS forecast.
Our base-case forecast reaches $7.30 around 2034.
Implied market cap at $7.30: $530.06M
The multi-year forecast shows bullish sentiment from 2027 onward, with 2026 labeled as neutral.
For 2026, the min is $3.08, the avg is $3.50, the max is $4.87, and the ROI is 0%.
For 2030, the avg is $5.52 and the ROI is 57.7%. The forecast also projects a move toward $10.36 on average by 2040, with a 196% ROI, and further uphill progression toward 2050 with an avg of $22.64 and a 546.9% ROI. The 2050 forecast also shows a min of $12.02 and a max of $43.81, with bullish sentiment prevailing.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $5.52 with a 57.7% ROI; the 2030 min is $3.99 and the max is $8.25, and the sentiment is BULLISH.
The 2027–2035 period is forecast as BULLISH with rising averages (e.g., 2027 avg $4.31, 2028 avg $5.03, 2029 avg $5.84, 2030 avg $5.52). The 2026 year is NEUTRAL with an avg of $3.50 and ROI of 0%.
No. The 2050 max is $43.81, while the 2040 max is $18.20, based on the forecasted ranges.
Current price is $3.50. The 30-day range is $2.86 to $4.28.
For 2040, the avg is $10.36 with a 196% ROI. For 2050, the avg is $22.64 with a 546.9% ROI.
Cellectis S.A. Community Discussion
0Share your Cellectis S.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.